The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CodeBreak 100: Activity of AMG 510, a novel small molecule inhibitor of KRASG12C, in patients with advanced colorectal cancer.
Marwan Fakih
Consulting or Advisory Role - Amgen; Array BioPharma; Genentech/Roche
Speakers' Bureau - Amgen; Taiho Pharmaceutical
Research Funding - Amgen (Inst); AstraZeneca (Inst); Novartis (Inst)
Jayesh Desai
Consulting or Advisory Role - Amgen (Inst); BeiGene; Biocon; Eisai; Lilly
Research Funding - AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Novartis (Inst); Roche (Inst)
Yasutoshi Kuboki
Honoraria - Bayer; Lilly Japan; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical
Consulting or Advisory Role - Boehringer Ingelheim; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
John H. Strickler
Consulting or Advisory Role - Amgen; Bayer; Chengdu Kanghong Biotech; Genentech/Roche; OncoMed; Proteus Digital Health; Seagen
Research Funding - Abbvie (Inst); Amgen (Inst); Curegenix; Exelixis (Inst); Gilead Sciences (Inst); Leap Therapeutics (Inst); Macrogenics (Inst); MedImmune (Inst); Nektar (Inst); Roche/Genentech (Inst); Seagen (Inst)
Timothy Jay Price
Consulting or Advisory Role - Amgen; Merck Serono (Inst); Roche (Inst)
Research Funding - AMGEN (Inst)
Travel, Accommodations, Expenses - Amgen
Greg Andrew Durm
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
Gerald Steven Falchook
Employment - HealthONE; Sarah Cannon Research Institute
Consulting or Advisory Role - EMD Serono; Fujifilm (Inst)
Speakers' Bureau - Total Health Conferencing
Research Funding - 3-V Biosciences (Inst); Abbisko (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Aileron Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); AstraZeneca (Inst); BeiGene (Inst); Bioatla (Inst); Biothera (Inst); Celgene (Inst); Celldex (Inst); Ciclomed (Inst); Curegenix (Inst); Curis (Inst); Cyteir (Inst); Daiichi Sankyo (Inst); DelMar Pharmaceuticals (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Exelixis (Inst); Fujifilm (Inst); Genmab (Inst); Hutchison MediPharma (Inst); Ignyta (Inst); Incyte (Inst); Jacobio (Inst); Jounce Therapeutics (Inst); Kolltan Pharmaceuticals (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); miRNA Therapeutics (Inst); Novartis (Inst); OncoMed (Inst); Oncorus (Inst); poseida therapeutics (Inst); Precision Oncology (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Rgenix (Inst); Ribon Therapeutics (Inst); Strategia Therapeutics (Inst); Syndax (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tesaro (Inst); Tocagen (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Handbook of Targeted Cancer Therapy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; EMD Serono; Fujifilm; Millennium; Sarah Cannon Research Institute
Crystal S. Denlinger
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Lilly; Merck; Taiho Pharmaceutical
Research Funding - Agios (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genmab (Inst); Lilly (Inst); Lycera (Inst); Macrogenics (Inst); MedImmune (Inst); Merrimack (Inst); Sanofi (Inst); Zymeworks (Inst)
John C. Krauss
Research Funding - Abbvie (Inst); ACCRU (Inst); Amgen (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Ignyta (Inst); Isofol Medical (Inst); NSABP FOUNDATION (Inst); NSABP Foundation (Inst); OncoMed (Inst); Shire (Inst); XBiotech (Inst)
Geoffrey Shapiro
Consulting or Advisory Role - Almac Diagnostics; Angiex; Artios; Astex Pharmaceuticals; Atrin Pharmaceuticals; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Boehringer Ingelheim; Concarlo; Cybrexa Therapeutics; Daiichi Sankyo; Fusion Pharmaceuticals; G1 Therapeutics; Ipsen; Lilly; Merck Serono; Pfizer; Roche; Seagen; Sierra Oncology
Research Funding - Aileron Therapeutics (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CanBas (Inst); Cellceutix (Inst); Clovis Oncology (Inst); Covidien (Inst); Curis (Inst); Cyclacel (Inst); Esperas Pharma (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PTC Therapeutics (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Sierra Oncology (Inst); Syros Pharmaceuticals (Inst); Tensha Therapeutics (Inst); Tesaro (Inst); Vertex (Inst)
Patents, Royalties, Other Intellectual Property - Patent #: 9872874 Title: Dosage regimen for sapacitabine and seliciclib Issue Date: 1/23/2018; Provisional Patent #:62/538,319 Title: Compositions and methods for predicting response and resistance to CDK4/6 inhibition Filed: 7/28/17
Travel, Accommodations, Expenses - Bayer; Bicycle Therapeutics; G1 Therapeutics; Lilly; Pfizer; Sierra Oncology
Tae Won Kim
Employment - Asan Medical Center
Research Funding - AstraZeneca (Inst); Merck Serono (Inst); Sanofi (Inst)
Keunchil Park
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Daiichi Sankyo; Hanmi; Lilly; LOXO; Merck KGaA; MSD; Novartis; Ono Pharmaceutical; Roche
Speakers' Bureau - AZD; Boehringer Ingelheim
Research Funding - AstraZeneca; MSD Oncology
Andrew L. Coveler
Consulting or Advisory Role - Abbvie; Halozyme; Merrimack; Seagen
Research Funding - AbGenomics International (Inst); Amgen (Inst); Amgen (Inst); Genentech (Inst); Gilead Sciences (Inst); Halozyme (Inst); Immunomedics (Inst); Lilly (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novocure (Inst); Onconova Therapeutics (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); XBiotech (Inst)
Travel, Accommodations, Expenses - Abbvie; Halozyme
Pamela N. Munster
Leadership - Alessa Therapeutics
Stock and Other Ownership Interests - Alessa Therapeutics
Honoraria - AtlasMedx; Celgene; CStone Pharmaceuticals; Epigene; McVeigh; Prometheus (I); Xynomic Pharma (Inst)
Consulting or Advisory Role - HUYA Bioscience International
Research Funding - Andes Biotechnologies (Inst); Biomarin (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Intellikine (Inst); Merck (Inst); Merrimack (Inst); Nektar (Inst); Novartis (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); oncosec (Inst); Pfizer (Inst); Piramal Life Science (Inst); Plexxikon (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - UCSF patent on using silastic implants to deliver anticancer agents
Bob T. Li
Consulting or Advisory Role - Guardant Health; Hengrui Therapeutics
Research Funding - Amgen (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); GRAIL (Inst); Guardant Health (Inst); Hengrui Therapeutics (Inst); Lilly (Inst); MORE Health (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - US62/514,661 (Inst); US62/685,057 (Inst)
June Kim
Employment - Amgen
Stock and Other Ownership Interests - Amgen
Haby Adel Henary
Employment - Amgen
Stock and Other Ownership Interests - Amgen
Gataree Ngarmchamnanrith
Employment - Amgen
Stock and Other Ownership Interests - Amgen
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; Oncorena; Presagia
Consulting or Advisory Role - Alphasights; Axiom Biotechnologies; Bayer; Genentech; Gerson Lehrman Group; GroupH; Guidepoint Global; Infinity Pharmaceuticals; Medscape; Merrimack; Numab; Pfizer; PrimE Oncology; Seagen; Takeda; Trieza Therapeutics; WebMD
Research Funding - Abbvie; Adaptimmune; Aldai Norte; Amgen; AstraZeneca/MedImmune; Bayer; Daiichi Sankyo; Fate Therapeutics; Genentech; Infinity Pharmaceuticals; Kite, a Gilead company; Kura Oncology; MedImmune; Mirati Therapeutics; Molecular Templates; National Cancer Institute; Pfizer; Seagen; Shattuck Labs; TCR2 Therapeutics; TP Therapeutics
Travel, Accommodations, Expenses - AACR; ASCO; Bayer Schering Pharma; Genmab; Society for Immunotherapy of Cancer